JMB-HEADER RAS-JOURNALS EIMB Pleiades Publishing

RUS

             

ENG

YearIMPACT-FACTOR
2024  1,200
2023  1,500
2022  1,200
2021  1,540
2020  1,374
2019  1,023
2018  0,932
2017  0,977
2016  0,799
2015  0,662
2014  0,740
2013  0,739
2012  0,637
2011  0,658
2010  0,654
2009  0,570
2008  0,849
2007  0,805
2006  0,330
2005  0,435
2004  0,623
2003  0,567
2002  0,641
2001  0,490
2000  0,477
1999  0,762
1998  0,785
1997  0,507
1996  0,518
1995  0,502
Vol 59(2025) N 3 p. 320-335; DOI 10.1134/S0026893325700025 Full Text

T.S. Usenko1,2*, S.N. Pchelina1,2

Parkinson's Disease Associated with Mutations in the LRRK2 Gene: Approaches to Therapy

1Konstantinov St. Petersburg Nuclear Physics Institute, National Research Center Kurchatov Institute, Gatchina, 188300 Russia
2Pavlov First St. Petersburg State Medical University, St. Petersburg, 197022 Russia


*usenko_ts@pnpi.nrcki.ru
Received - 2024-07-27; Revised - 2024-10-10; Accepted - 2024-11-23

Leucine-rich repeat kinase 2 (LRRK2) belongs to the subfamily of tyrosine kinase-like kinases, the main function of which is to catalyze the transfer of γ-phosphate from ATP to the substrate in the cell due to the kinase domains. The exact functions of LRRK2 in the cell remain unknown. It has been shown that mutations in the LRRK2 gene, which are the cause of the development of the most common autosomal dominant form of neurodegenerative disease, Parkinson's disease (PD), mainly lead to a pathological increase in kinase activity. This review describes the structure of LRRK2 and the functional activity of LRRK2 kinase in the form of a monomer, dimer, and even a tetramer and describes the effect of mutations in the LRRK2 gene on the structure and kinase activity of the LRRK2 enzyme. Understanding the structure and functions of LRRK2 opens up new prospects for using it as a target for PD therapy.

Parkinson's disease, LRRK2, structure, functions, Parkinson's disease therapy



JMB-FOOTER RAS-JOURNALS